<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00840</drugbank-id>
  <drugbank-id>APRD01023</drugbank-id>
  <name>Hydroxypropyl cellulose</name>
  <description>Hydroxypropyl cellulose is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated forming -OCH2CH(OH)CH3 groups. Lacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes. As a food additive, hydroxypropyl cellulose is used as a thickener and as an emulsion stabilizer.</description>
  <cas-number>9004-64-2</cas-number>
  <unii>RFW2ET671P</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1252</ref-id>
        <pubmed-id>21178699</pubmed-id>
        <citation>Wander AH: Long-term use of hydroxypropyl cellulose ophthalmic insert to relieve symptoms of dry eye in a contact lens wearer: case-based experience. Eye Contact Lens. 2011 Jan;37(1):39-44. doi: 10.1097/ICL.0b013e3181f84f92.</citation>
      </article>
      <article>
        <ref-id>A1253</ref-id>
        <pubmed-id>20858108</pubmed-id>
        <citation>McDonald M, D'Aversa G, Perry HD, Wittpenn JR, Nelinson DS: Correlating patient-reported response to hydroxypropyl cellulose ophthalmic insert (LACRISERT(R)) therapy with clinical outcomes: tools for predicting response. Curr Eye Res. 2010 Oct;35(10):880-7. doi: 10.3109/02713683.2010.495811.</citation>
      </article>
      <article>
        <ref-id>A1254</ref-id>
        <pubmed-id>20847657</pubmed-id>
        <citation>Luchs JI, Nelinson DS, Macy JI: Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: findings from a patient registry. Cornea. 2010 Dec;29(12):1417-27. doi: 10.1097/ICO.0b013e3181e3f05b.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Seiji Orii, Yukio Sasagawa, Akinori Ito, Maruyama, Hiromi, Yoshiteru Sakai, "Process of producing hydroxypropyl cellulose." U.S. Patent US4292426, issued April, 1964.</synthesis-reference>
  <indication>Used to relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes.</indication>
  <pharmacodynamics>Hydroxypropyl cellulose (cellulose, 2-hydroxypropyl ether) is a derivative of cellulose with both water solubility and organic solubility. Hydroxypropyl cellulose acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Hydroxypropyl cellulose also acts to lubricate and protect the eye. Hydroxypropyl cellulose usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision. Progressive visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed.</pharmacodynamics>
  <mechanism-of-action>Hydroxypropyl cellulose is a derivative of cellulose that is soluble in both water and organic solvents. It is particularly good at trapping water and producing a film that serves as a barrier to water loss. Hydroxypropyl cellulose possesses good surface activity but does not gel as it forms open helical coils. In general Hydroxypropyl cellulose is a water-soluble thickener, emulsifier and film-former often used in tablet coating.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;=10200 mg/kg (oral, rat)</toxicity>
  <metabolism>Hydroxypropyl cellulose is a physiologically inert substance. In a study of rats fed hydroxypropyl cellulose or unmodified cellulose at levels up to 5% of their diet, it was found that the two were biologically equivalent in that neither was metabolized.</metabolism>
  <absorption>Studies conducted in rats fed 14 C-labeled hydroxypropyl cellulose demonstrated that when orally administered, hydroxypropyl cellulose is not absorbed from the gastrointestinal tract and is quantitatively excreted in the feces.</absorption>
  <half-life/>
  <protein-binding>None</protein-binding>
  <route-of-elimination>Studies conducted in rats fed 14C-labeled hydroxypropyl cellulose demonstrated that when orally administered, hydroxypropyl cellulose is not absorbed from the gastrointestinal tract and is quantitatively excreted in the feces.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Cellulose hydroxypropyl ether</synonym>
    <synonym language="english" coder="">Cellulose, 2-hydroxypropyl ether</synonym>
    <synonym language="spanish" coder="inn">Hiprolosa</synonym>
    <synonym language="german" coder="inn">Hydroxypropyl cellulose</synonym>
    <synonym language="english" coder="">Hydroxypropyl cellulose (type H)</synonym>
    <synonym language="english" coder="dcf">Hydroxypropylcellulose</synonym>
    <synonym language="french" coder="inn">Hyprolose</synonym>
    <synonym language="latin" coder="inn">Hyprolosum</synonym>
    <synonym language="english" coder="">Modified cellulose</synonym>
  </synonyms>
  <products>
    <product>
      <name>Lacrisert</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-06-01</started-marketing-on>
      <ended-marketing-on>2009-05-31</ended-marketing-on>
      <dosage-form>Insert</dosage-form>
      <strength>5 mg/1</strength>
      <route>Conjunctival</route>
      <fda-application-number>NDA018771</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lacrisert</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-800</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Pellet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA018771</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lacrisert</name>
      <labeller>Aton Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>25010-805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-06-01</started-marketing-on>
      <ended-marketing-on>2016-09-21</ended-marketing-on>
      <dosage-form>Pellet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA018771</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lacrisert</name>
      <labeller>Aton Pharma Inc Division Of Valeant Pharmaceuticals North America Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250624</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Insert</dosage-form>
      <strength>5 mg</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>A-Gel</name>
      <company>Fresenius Kabi</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Lacrisert</name>
      <ingredients>Hydroxypropyl cellulose</ingredients>
    </mixture>
    <mixture>
      <name>Lacrisert</name>
      <ingredients>Hydroxypropyl cellulose</ingredients>
    </mixture>
    <mixture>
      <name>Lacrisert</name>
      <ingredients>Hydroxypropyl cellulose</ingredients>
    </mixture>
    <mixture>
      <name>Lacrisert</name>
      <ingredients>Hydroxypropyl cellulose</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Aton Pharma Inc.</name>
      <url>http://www.atonrx.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Merck &amp; Co.</name>
      <url>http://www.merck.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Aton pharma inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Lacrisert 5 mg eye insert</description>
      <cost currency="USD">3.68</cost>
      <unit>insert</unit>
    </price>
    <price>
      <description>Lacrisert 60 5 mg Insert Box</description>
      <cost currency="USD">281.99</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Hydroxypropylcellulose powd</description>
      <cost currency="USD">0.51</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Artificial Tears</category>
      <mesh-id>D065346</mesh-id>
    </category>
    <category>
      <category>Biopolymers</category>
      <mesh-id>D001704</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Demulcent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Demulcent Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glucans</category>
      <mesh-id>D005936</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Ophthalmics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Polysaccharides</category>
      <mesh-id>D011134</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Insert</form>
      <route>Conjunctival</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Insert</form>
      <route>Ophthalmic</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Pellet</form>
      <route>Ophthalmic</route>
      <strength>5 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>52:13.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00840.pdf?1265922812</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00840.pdf?1265922749</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13317</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508483</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01536</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746492</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Hydroxypropyl_cellulose</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201471</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/lacrisert.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/artificial-tear-insert.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>